Aevi Genomic Medicine (NASDAQ:GNMX) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk and Volatility

Aevi Genomic Medicine has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500.

Profitability

This table compares Aevi Genomic Medicine and Fennec Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aevi Genomic Medicine N/A -152.07% -122.06%
Fennec Pharmaceuticals N/A -36.74% -34.74%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Aevi Genomic Medicine and Fennec Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aevi Genomic Medicine 0 1 0 0 2.00
Fennec Pharmaceuticals 0 0 4 0 3.00

Fennec Pharmaceuticals has a consensus price target of $17.00, suggesting a potential upside of 143.20%. Given Fennec Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Fennec Pharmaceuticals is more favorable than Aevi Genomic Medicine.

Valuation and Earnings

This table compares Aevi Genomic Medicine and Fennec Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aevi Genomic Medicine N/A N/A -$34.71 million ($0.83) -0.25
Fennec Pharmaceuticals N/A N/A -$7.04 million ($0.47) -14.87

Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Aevi Genomic Medicine, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

19.6% of Aevi Genomic Medicine shares are held by institutional investors. Comparatively, 47.4% of Fennec Pharmaceuticals shares are held by institutional investors. 11.7% of Aevi Genomic Medicine shares are held by company insiders. Comparatively, 9.9% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Fennec Pharmaceuticals beats Aevi Genomic Medicine on 8 of the 11 factors compared between the two stocks.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.